89088-69-7

Usage

Uses

Used in Pharmaceutical Industry:
1-Methyl-1H-imidazol-4-amine hydrochloride is used as a precursor in the synthesis of various drugs for its ability to contribute to the development of new pharmaceuticals with potential therapeutic effects.
Used in Research and Development:
In the field of drug development, 1-Methyl-1H-imidazol-4-amine hydrochloride is used as a research compound to explore its potential in creating new medications and understanding its interactions with biological systems.
Used in Neuroscience:
1-Methyl-1H-imidazol-4-amine hydrochloride is utilized as a research tool in neuroscience to study central nervous system disorders, aiding in the advancement of knowledge about these conditions and the discovery of new treatment methods.
Used in Chemical Reactions:
As a reagent, 1-Methyl-1H-imidazol-4-amine hydrochloride is employed in various chemical reactions, facilitating the synthesis of complex organic molecules and contributing to the advancement of chemical research.
Overall, 1-methyl-1H-imidazol-4-amine hydrochloride is an important and versatile chemical compound with numerous applications in research, pharmaceutical development, and the study of neurological conditions.

Upstream product

• 3034-41-1 1-methyl-4-nitro-1H-imidazole 
• 79578-98-6 1-methyl-1H-imidazol-4-amine 

Downstream Products

• 1220517-76-9 2-chloro-N-(1-methyl-1H-imidazol-4-yl)-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine 
• 1220517-78-1 2-chloro-N-(1-methyl-1H-imidazol-4-yl)-5-[(4-methylphenyl)sulfonyl]-5H-pyrrolo[3,2-d]pyrimidin-4-amine 

Relevant academic research and scientific papers

Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives as Potent and Selective p21-Activated Kinase 4 (PAK4) Inhibitors

Herein, we report the discovery and characterization of a novel class of PAK4 inhibitors with a quinazoline scaffold. Based on the shape and chemical composition of the ATP-binding pocket of PAKs, we chose a 2,4-diaminoquinazoline series of inhibitors as a starting point. Guided by X-ray crystallography and a structure-based drug design (SBDD) approach, a series of novel 4-aminoquinazoline-2-carboxamide PAK4 inhibitors were designed and synthesized. The inhibitors' selectivity, therapeutic potency, and pharmaceutical properties were optimized. One of the best compounds, 31 (CZh226), showed remarkable PAK4 selectivity (346-fold vs PAK1) and favorable kinase selectivity profile. Moreover, this compound potently inhibited the migration and invasion of A549 tumor cells by regulating the PAK4-directed downstream signaling pathways in vitro. Taken together, these data support the further development of 31 as a lead compound for PAK4-targeted anticancer drug discovery and as a valuable research probe for the further biological investigation of group II PAKs.

Discovery of 1-methyl-1 H-imidazole derivatives as potent Jak2 inhibitors

Structure based design, synthesis, and biological evaluation of a novel series of 1-methyl-1H-imidazole, as potent Jak2 inhibitors to modulate the Jak/STAT pathway, are described. Using the C-ring fragment from our first clinical candidate AZD1480 (24), optimization of the series led to the discovery of compound 19a, a potent, orally bioavailable Jak2 inhibitor. Compound 19a displayed a high level of cellular activity in hematopoietic cell lines harboring the V617F mutation and in murine BaF3 TEL-Jak2 cells. Compound 19a demonstrated significant tumor growth inhibition in a UKE-1 xenograft model within a well-tolerated dose range.

HETEROCYCLIC JAK KINASE INHIBITORS

The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer